Government Warns About New Class of Type 2 Diabetes Drugs
An article in the New York Daily News reported that the U.S. Food and Drug Administration (FDA) warned that a class of type 2 diabetes drugs called SGLT2 inhibitors could cause “dangerously high levels of blood acids.” The article goes on to say that the high levels of blood acids could lead to hospitalization. The article specifically mentions Invokana as an SGLT2 inhibitor. High levels of blood acids, called ketones, could lead to a condition known as ketoacidosis which can require a trip to the emergency room to treat. The FDA stated that it continues to see reports of ketoacidosis in patients using SGLT2 inhibitors in its Adverse Event Reporting System.